PresentationYou may type in a question at any time during the webinar, you can do this through the Q&A panel, which appears on the right side of the webinar presentation. If you look to the bottom tray of your window, there is a series of widgets to enhance your webinar experience. And with that, I'll turn it over to Marielle.Great. Good morning, everyone. I'm Alexandra Byrne. I'm a reporter at GenomeWeb, and I will be your moderator for today's webinar. The title of today's webinar is beyond the genome: Me ...

LAS VEGAS, NV / ACCESS Newswire / October 1, 2025 / Hypha Labs, Inc. (OTCQB:FUNI), a biotechnology company pioneering the development of functional mushroom technologies, today announced the official launch of Phase II in its strategic partnership with Tryptomics, uniting Hypha's patented Mushroom Acceleratorâ"¢ platform with Tryptomics On-Siteâ"¢ Science Services & their contract R&D Metabolomics Pipeline to develop Hypha Labs proprietary varieties of bioreactor-optimized species and providing the gold- st ...

TROY, Mich.--(BUSINESS WIRE)--ZIVO Bioscience, Inc. (OTCQB: ZIVO), a biotech and agtech R&D company engaged in the development of therapeutic and nutritional products derived from proprietary algal cultures, today issued the following letter to shareholders from Chairman, President and Chief Executive Officer John B. Payne. Dear Fellow Shareholders, I am pleased to provide you with this important update on the significant progress by ZIVO Bioscience and a review of our exciting future direc. ...

Core Viewpoint - Ginkgo Bioworks is settling multiple derivative actions with a total payment of $4,125,000 to be made by the Individual Defendants' Insurers, which is intended to benefit the company and its shareholders [5][7][10]. Summary by Sections Settlement Details - The settlement amount of $4,125,000 will be paid to Ginkgo within 30 days after the court enters the judgment [5]. - The settlement includes all fees and expenses of Plaintiffs' Counsel and Service Awards, which will be paid if approved by the court [5][8]. - Ginkgo will terminate a specific contract and implement corporate governance reforms for at least three years as part of the settlement [6]. Court Approval - A settlement hearing is scheduled for December 18, 2025, where the court will determine the fairness and adequacy of the settlement [9][10]. - Current Ginkgo stockholders have the right to appear at the hearing and object to the settlement or fee amounts [11][12]. Governance Reforms - The Board of Ginkgo has committed to adopting and maintaining comprehensive corporate governance and internal control reforms as part of the settlement [6][7]. - The Board believes the settlement confers substantial benefits to Ginkgo and its stockholders [7]. Legal Proceedings - The derivative actions are being settled in both the Northern District of California and Delaware Chancery Court [5][10]. - The settlement is part of a broader effort to address claims asserted in the derivative actions [6].

Core Viewpoint - PCI Biotech Holding ASA has decided to discontinue the development of its photochemical lysis (PCL) technology for viral vector manufacturing due to insufficient progress towards its 2025 goals [1][3] Group 1: Development Progress - The company aimed to demonstrate improved yield in mini benchtop bioreactors by 2025, but efforts have not yielded convincing results [1][2] - Additional initiatives were undertaken following the preliminary 2024 Interim Report and the Annual Report 2024, but these did not lead to satisfactory outcomes [2] Group 2: Project Risks and Financial Position - Insufficient progress has extended project timelines and increased resource requirements, raising the overall project risk to an unacceptable level [3] - As of June 2025, PCI Biotech's cash position was NOK 13.6 million, which is expected to sustain operations into Q4 2025, but there is uncertainty regarding the ability to secure additional financing [4] - The company is evaluating its future, considering options such as a potential sale, merger, or complete wind-down of operations [4]

Company Overview - Ginkgo Bioworks is focused on building a leading platform for cell programming and biosecurity [1] - The company offers customizable R&D packages, including protein engineering and nucleic acid design, to accelerate innovation in therapeutics, diagnostics, and manufacturing [3] - Ginkgo Automation provides modular laboratory automation solutions to enhance scientific productivity [3] - Ginkgo Biosecurity is developing next-generation infrastructure and technologies to address biological threats [3] Upcoming Events - Ginkgo Bioworks will host a presentation and Q&A session on August 7, 2025, to review its business performance for Q2 2025 [1] - The session will begin at 5:30 p.m. ET and will be available via webcast on the company's investor relations website [2] - Questions can be submitted in advance through social media or email [2]

Core Insights - The focus is on sustainable wealth growth through investments in R&D biotech [1] - The author expresses a personal beneficial long position in QURE shares, indicating confidence in the company's potential [1] Company and Industry Summary - The article emphasizes the importance of research and development in the biotechnology sector as a means to achieve sustainable investment returns [1] - The author highlights the relevance of their academic background in Cell Physiology and Bio-organic Chemistry to their investment strategy in biotech [1]

Financial Data and Key Metrics Changes - Total operating expenses for Q4 2024 were $20.0 million, roughly equal to Q4 2023 and $0.9 million above the previous quarter [35] - Net loss for Q4 2024 was $17.6 million compared to $17.0 million in the prior-year period [36] - For fiscal year 2024, net loss was $70.8 million, an increase of 11% year-over-year from $63.7 million in fiscal year 2023 [37] Business Line Data and Key Metrics Changes - Research and development expenses in Q4 2024 were $12.8 million compared to $12.5 million in the prior-year period, while general and administrative expenses were $7.2 million in Q4 2024 compared to $7.5 million in the prior-year period [36] - Operating expenses for fiscal year 2024 were $81.5 million, an increase of 7% from $76.2 million in fiscal year 2023 [37] Market Data and Key Metrics Changes - The company ended the year with approximately $206 million in cash, cash equivalents, and investments compared to $264 million at the end of the previous year [39] Company Strategy and Development Direction - The company now expects the launch of its proteome analysis platform to occur in late 2026, focusing on reducing technical risk and maximizing performance [29][33] - The company plans to engage in significant partnerships to explore tau proteoform landscapes and aims to provide leading researchers access to its platform for tau proteoform-related studies in 2025 [30][31] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to deliver a game-changing product to the market, emphasizing the importance of rigorous financial discipline and operational adjustments to extend the cash runway through 2027 [33][41] - The company anticipates that 2025 will be a pivotal year for applying the platform's capabilities to important questions about tau proteoforms in Alzheimer's disease [30] Other Important Information - The company reduced its headcount by approximately 16% to align resources with development goals and extend its cash runway [33][38] - The company is focused on optimizing assay configurations and surface chemistry to enhance the performance of its platform [29][55] Q&A Session Summary Question: Could you elaborate on your plan to modify the assay configuration and surface chemistry? - Management explained that the modifications aim to enhance specific binding of affinity reagents to proteins and differentiate non-specific binding, addressing issues related to probe labeling and surface chemistry [48][49][52] Question: Does the planned change impact the cost structure of the platform? - Management indicated that the changes may have a positive impact on the consumable side and that the previously mentioned pricing of approximately $1 million for the instrument remains valid [54][55] Question: What are the key milestones and timing over 2025 and into 2026? - Management outlined milestones including providing access to the platform for tau proteoform studies, signing partnerships, and decoding a significant number of proteins from complex samples [82][84] Question: How does your platform's performance compare to other tau protein platforms? - Management highlighted that their platform uniquely measures proteoforms in high throughput and sensitivity, allowing for detailed insights into Alzheimer's disease [89][92] Question: Is the late 2026 launch for both broadscale discovery and targeted platforms? - Management clarified that both modalities are heading to market with different strategies, with broadscale discovery launching commercially in late 2026 while proteoform capabilities will be introduced through partnerships [95][100]

Financial Data and Key Metrics Changes - The company ended Q4 2024 with $562 million in cash and no bank debt, significantly exceeding its original cost-cutting target for 2024 [10][48] - Total company adjusted EBITDA in Q4 was negative $57 million, an improvement from negative $101 million in Q4 2023 [30] - Cash burn in Q4 2024 was $55 million, down from $114 million in Q3 2024, reflecting successful restructuring efforts [32][33] Business Line Data and Key Metrics Changes - Cell Engineering revenue for Q4 2024 was $35 million, up 29% year-over-year, driven by growth with large biopharma customers [15] - Biosecurity revenue in Q4 2024 was $9 million, with a full-year revenue of $53 million, down 51% from $108 million in 2023 due to the end of K-12 COVID testing contracts [23][24] - The company supported 138 active programs across 85 customers on the Cell Engineering platform in Q4 2024, a 5% increase in active programs year-over-year [17] Market Data and Key Metrics Changes - The government segment has been a source of growth, but uncertainties in this area are factored into the low end of revenue guidance for 2025 [38] - The company expects Cell Engineering revenue for 2025 to be in the range of $110 million to $130 million, with Biosecurity revenue guidance at least $50 million [39][40] Company Strategy and Development Direction - The company aims to reach adjusted EBITDA breakeven while maintaining a cash margin of safety, focusing on cost reduction and revenue expansion [10][12] - Ginkgo is expanding into life science tools and services, responding to market trends in biopharma for more data for AI models [44][46] - The company has achieved a $190 million annualized run rate reduction in spending through Q4 2024, exceeding initial targets [47] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the uncertain macro environment but is encouraged by early traction in tools offerings and the restructuring progress [42][43] - The company is optimistic about its competitive position in the biotech industry and plans to continue reducing cash burn while expanding revenue sources [48][50] - Management emphasizes the importance of maintaining a cash margin of safety to avoid dilutive fundraising [11][48] Other Important Information - The company has remediated its SOX material weakness, indicating improved financial reporting processes [43] - Ginkgo is leading an international consortium for a project worth up to EUR 24 million focused on point-of-care sequencing and metagenomic NGS [83][84] Q&A Session Summary Question: What are the ideal customer personas Ginkgo needs to close for new client acquisition - The ideal customer persona varies by product; for solutions deals, it is typically the head of R&D in large biopharma or the CEO in small biotech [89] - For data points, the target is usually a lead for a drug program, which allows for a wider engagement [90] - For automation, the focus is on automation leads responsible for building out new work cells [91]